News & Updates

Show Multimedia Only

Low-dose methotrexate-related melanoma risk considered negligible

09 Sep 2022 by

Individuals exposed to low-dose methotrexate risk developing melanoma, although the absolute risk increase remains very low, as shown in a recent meta-analysis.

09 Sep 2022

Topical combination, physical treatments best for mild-to-moderate acne

06 Sep 2022 by

Topical pharmacological treatment combinations, chemical peels, and photochemical therapy are deemed to be the best and the most effective options for mild-to-moderate acne vulgaris.

06 Sep 2022

No clear link between atopic dermatitis and venous thromboembolism

30 Aug 2022

There appears to be no evidence that atopic dermatitis or treatment with Janus kinase (JAK) inhibitors carries an increased risk of venous thromboembolism, according to a study.

30 Aug 2022

UK Biobank: As hard water levels increase, so does the burden of eczema

26 Aug 2022 by

Exposure to domestic hard water in high concentrations appears to go with a corresponding increase in the prevalence of eczema in adults, as reported in a UK study.

26 Aug 2022

Brepocitinib cream works in mild-to-moderate atopic dermatitis

25 Aug 2022

The topical cream brepocitinib, a small molecule tyrosine kinase 2, appears to be effective in the treatment of mild-to-moderate atopic dermatitis while being well tolerated, according to the results of a double-blind, dose-ranging phase IIb trial.

25 Aug 2022

OASIS-1: Thumbs up for mirikizumab in moderate-to-severe plaque psoriasis

23 Aug 2022 by

The interleukin (IL)-23 inhibitor mirikizumab demonstrates superior efficacy in the treatment of patients with moderate-to-severe plaque psoriasis as compared with placebo, with initial responses during induction preserved through the maintenance phase, according to the results of the phase III OASIS-1 trial.

23 Aug 2022

Hair loss common after COVID-19 infection

19 Aug 2022 by

There appears to be an increased risk of hair loss – a phenomenon called telogen effluvium – after COVID-19 infection.

19 Aug 2022

DPP4i-associated bullous pemphigoid shows distinct skin cytokine profile

13 Aug 2022

The cutaneous cytokine expression is different in patients with dipeptidyl peptidase 4 inhibitor (DPP4i)-associated bullous pemphigoid (BP), as opposed to those with typical BP, reports a new study.

13 Aug 2022

Secukinumab 300 mg leads to sustained improvements in PsA symptoms

12 Aug 2022 by

Treatment with secukinumab 300 mg significantly improves symptoms of biologic-naïve patients with psoriatic arthritis (PsA) compared with placebo, results from the CHOICE study have shown.

12 Aug 2022

Hidradenitis suppurativa: Treatment by specialist, with biologics dictate satisfaction

07 Aug 2022

Among patients with hidradenitis suppurativa, treatment satisfaction is high for those who are treated by a dermatologist and receive a biologic medication, a study has found.